Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type BioCentury Early data from Novo's CagriSema competitive with Lilly's Mounjaro Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Wegovy Cuts Food Noise, Cagrilintide Delivers Significant Weight Loss: Novo Nordisk Unveils New Data at EASD 2025 Clinical Trials
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols